Aktieanalys

Alzecure: Early Efficacy Signals from ACD856 “MAD” study - Redeye

Redeye Publicerad: 16 Sep 2022 16:08

Redeye is interested to learn more about today’s news from Alzecure. The release states that an exploratory analysis from its phase I “MAD” trial with ACD856, which targets mainly symptomatic Alzheimers, indicates that the drug candidate increases EEG activity in the brain, which in combination with the recent data on blood-brain-barrier penetration together are interesting early efficacy signals. We hope to learn more about this data and the future clinical program for ACD856 later this year.

Länk till analysen i sin helhet: https://www.redeye.se/research/855762/alzecure-early-efficacy-signals-from-acd856-mad-study?utm_source=finwire&utm_medium=RSS

Nyheter om AlzeCure Pharma

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!